HLA-restricted epitopes encoded by somatic mutation genes
JP2026090637APending Publication Date: 2026-06-02JOHNS HOPKINS UNIVERSITY
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- JOHNS HOPKINS UNIVERSITY
- Filing Date
- 2026-03-10
- Publication Date
- 2026-06-02
AI Technical Summary
Technical Problem
Existing antibodies are ineffective in targeting intracellular protein mutations associated with cancer due to their inability to access intracellular antigens, and immunotherapy targeting these mutations is limited to individual patients with specific MANAs.
Method used
Development of antibody variable regions and T cell receptors that specifically bind to complexes of HLA molecules and peptides containing mutant residues within intracellular epitopes, while avoiding wild-type forms, enabling therapeutic and diagnostic applications.
Benefits of technology
Provides a means to target intracellular cancer-related epitopes presented on the cell surface, allowing for personalized cancer therapy and monitoring.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026090637000001_ABST
Abstract
This invention provides single-stranded variable fragments (scFVs) specific to mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. [Solution] An isolated molecule comprising an antibody variable region that specifically binds to a complex of an HLA molecule and a peptide which is part of a protein, wherein the peptide contains a mutant residue, and the mutant residue is located within an intracellular epitope of the protein, the molecule does not specifically bind to the HLA molecule when the HLA molecule is not in the complex, and the molecule does not specifically bind to the peptide in its wild-type form.
Need to check novelty before this filing date? Find Prior Art